Carvedilol for Preventing Heart Problems in HER2 Positive Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Will I have to stop taking my current medications?
If you are currently taking a beta blocker, ARB, or ACE inhibitor, you cannot participate in the randomized part of the trial but may join the non-randomized observational group. Additionally, you must not take certain medications like B2 agonists, bosutinib, and others during the study.
Is carvedilol safe for humans?
How does the drug carvedilol differ from other treatments for preventing heart problems in HER2 positive breast cancer?
Carvedilol is unique because it not only blocks certain receptors in the heart to improve heart function but also has antioxidant properties that may protect against heart damage caused by cancer treatments like anthracyclines. This makes it potentially effective in preventing heart problems in breast cancer patients, which is not a standard use for other heart medications.12456
What data supports the effectiveness of the drug Carvedilol in preventing heart problems in HER2 positive breast cancer patients?
Who Is on the Research Team?
Justin Floyd
Principal Investigator
SWOG Cancer Research Network
Are You a Good Fit for This Trial?
This trial is for adults with HER-2-positive metastatic breast cancer who are starting or continuing trastuzumab-based therapy. They must have normal heart function, blood pressure, and not be on certain heart medications. Pregnant or nursing individuals can't join, nor those with other recent cancers except some specific cases.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive carvedilol or no intervention for up to 108 weeks, with courses repeating every 12 weeks for those on carvedilol
Observation
Participants undergo observation for cardiac events and other outcomes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Carvedilol
Find a Clinic Near You
Who Is Running the Clinical Trial?
Southwest Oncology Group
Lead Sponsor
SWOG Cancer Research Network
Lead Sponsor
National Cancer Institute (NCI)
Collaborator